Please use this identifier to cite or link to this item: https://doi.org/10.1155/2015/903524
Title: Influence of Acarbose on Plasma Glucose Fluctuations in Insulin-Treated Patients with Type 2 Diabetes: A Pilot Study
Authors: Li, F.-F
Xu, X.-H
Fu, L.-Y
Su, X.-F
Wu, J.-D
Lu, C.-F
Ye, L 
Ma, J.-H
Keywords: acarbose
glucose
hemoglobin A1c
insulin
recombinant human insulin
add on therapy
adult
aged
area under the curve
Article
biosensor
blood glucose monitoring
combination chemotherapy
continuous glucose monitoring system
controlled study
drug dose titration
drug efficacy
female
glucose blood level
human
hyperglycemia
hypoglycemia
maintenance therapy
major clinical study
male
monotherapy
multiple cycle treatment
non insulin dependent diabetes mellitus
pilot study
priority journal
randomized controlled trial
treatment duration
Issue Date: 2015
Citation: Li, F.-F, Xu, X.-H, Fu, L.-Y, Su, X.-F, Wu, J.-D, Lu, C.-F, Ye, L, Ma, J.-H (2015). Influence of Acarbose on Plasma Glucose Fluctuations in Insulin-Treated Patients with Type 2 Diabetes: A Pilot Study. International Journal of Endocrinology 2015 : 903524. ScholarBank@NUS Repository. https://doi.org/10.1155/2015/903524
Rights: Attribution 4.0 International
Abstract: Background and Aims. To evaluate the effect of adding acarbose on glycemic excursions measured by continuous glucose monitoring system (CGMS) in patients with type 2 diabetes mellitus (T2DM) already on insulin therapy. Materials and Methods. This was an opened and unblended study. 134 patients with T2DM were recruited. After initial rapidly corrected hyperglycaemia by continuous subcutaneous insulin infusion (CSII) for 7 d, a 4-6-day premixed insulin titration period subsequently followed. Patients were then randomized 1: 1 to acarbose plus insulin group or insulin therapy group for 2 weeks. CGMS was used to measure glucose fluctuations for at least 3 days after therapy cessation. Results. Patients in acarbose plus insulin group achieved a significant improvement of MAGE compared to that of insulin therapy only group (5.56 ± 2.16 versus 7.50 ± 3.28 mmol/L, P = 0.0 44), accompanied by a significant decrease in the incremental AUC of plasma glucose concentration above 10.0 mmol/L (0.5 [ 0.03, 0.9 ] versus 0.85 [ 0.23,1.4 ] mmol/L per day, P = 0.037). Conclusions. Add-on acarbose to insulin therapy further improves glucose fluctuation in patients with T2DM. This study was registered with ClinicalTrials.gov registration number ChiCTR-TRC-11001218. © 2015 Feng-fei Li et al.
Source Title: International Journal of Endocrinology
URI: https://scholarbank.nus.edu.sg/handle/10635/180926
ISSN: 16878337
DOI: 10.1155/2015/903524
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1155_2015_903524.pdf1.35 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

18
checked on Nov 25, 2020

Page view(s)

16
checked on Nov 26, 2020

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons